H.C. Wainwright has increased its price target for Cognition Therapeutics (CGTX) to $6 from $5, while keeping a Buy rating on the shares. This adjustment comes after the company announced positive top-line results from the Phase 2 SHIMMER trial of its leading candidate, CT1812, a sigma-2 receptor modulator, in patients with dementia with Lewy bodies. The firm has incorporated the dementia with Lewy bodies indication into its valuation assessment, assigning it a 30% likelihood of approval.
Cognition Therapeutics Price Target Increased by H.C. Wainwright

Stay Updated with Our Daily Newsletter
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.
Related News
Sources
Cognition Therapeutics price target raised to $6 from $5 at H.C. Wainwright
markets.businessinsider.comDec 19, 2024